Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.medcle.2020.06.012 http://scihub22266oqcxt.onion/10.1016/j.medcle.2020.06.012 32953990!7486822!32953990     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Med+Clin+(Engl+Ed) 2020 ; 155 (7): 281-287 Nephropedia Template TP {{tp|p=32953990|t=2020. Potential drug-drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir |pdf=|usr=}}{{32953990}} gab.com Text Potential drug-drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir JO: Med Clin (Engl Ed) http://www.kidney.de/pget.php?&tw=1&pmid=32953990 #FOAvip OBJECTIVES: To determine the prevalence of potential interactions in COVID19 patients receiving lopinavir/ritonavir (LPV/r). The secondary objective was to develop recommendations and identify the risk factors associated with presenting potential interactions with LPV/r. SUBJECTS AND METHODS: Cross-sectional and multicenter study with the participation of 2 hospitals. COVID 19 patients over 18 years of age, admitted to hospital and under treatment with LPV/r were included. A screening of potential interactions related to LPV/r and home and hospital medication was carried out. Lexicomp(R) (Uptodate), HIV-drug interactions and COVID-drug interactions were used as the query database. RESULTS: 361 patients with a mean age of 62.77?+/-?14.64 years were included, where 59.6% (n?=?215) were men. 62.3% (n?=?225) had 1 or more potential interactions and 26, 87% (n?=?97) 2 or more. The independent variables associated with presenting >/=1 potential interactions were age (>65) (OR 1.95; 95% CI 1.06-3.59, P?=?.033), ICU admission (OR 9.22; CI 95% 1.98-42.93; P?=?.005), previous respiratory pathology (OR 2.90; 95% CI 1.15-7.36; P?=?.024), psychiatric (OR 4.14; 95 CI% 1.36-12.61; P?=?.013), dyslipidemia (OR 3.21; 95% CI 1.63-6.35; P?=?.001) and the number of drugs prescribed (OR 4.33; 95% CI 2.40-7.81; P?=?.000). CONCLUSION: The prevalence of potential interactions in COVD 19 patient undergoing treatment with LPV/r is high, with age (>65), ICU admission, previous respiratory and psychiatric pathology, dyslipidemia and the number of prescribed drugs acting as risk factors. Twit Text FOAVip Potential drug-drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir ????Med Clin (Engl Ed) http://www.kidney.de/pget.php?&tw=1&pmid=32953990 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32953990 #FOAvip English Wikipedia <ref>{{Cite pmid|32953990}}</ref> Potential drug-drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir #MMPMID32953990 Brandariz-Nunez D; Correas-Sanahuja M; Guarc E; Picon R; Garcia B; Gil R Med Clin (Engl Ed) 2020[Oct]; 155 (7): 281-287 PMID32953990show ga OBJECTIVES: To determine the prevalence of potential interactions in COVID19 patients receiving lopinavir/ritonavir (LPV/r). The secondary objective was to develop recommendations and identify the risk factors associated with presenting potential interactions with LPV/r. SUBJECTS AND METHODS: Cross-sectional and multicenter study with the participation of 2 hospitals. COVID 19 patients over 18 years of age, admitted to hospital and under treatment with LPV/r were included. A screening of potential interactions related to LPV/r and home and hospital medication was carried out. Lexicomp(R) (Uptodate), HIV-drug interactions and COVID-drug interactions were used as the query database. RESULTS: 361 patients with a mean age of 62.77?+/-?14.64 years were included, where 59.6% (n?=?215) were men. 62.3% (n?=?225) had 1 or more potential interactions and 26, 87% (n?=?97) 2 or more. The independent variables associated with presenting >/=1 potential interactions were age (>65) (OR 1.95; 95% CI 1.06-3.59, P?=?.033), ICU admission (OR 9.22; CI 95% 1.98-42.93; P?=?.005), previous respiratory pathology (OR 2.90; 95% CI 1.15-7.36; P?=?.024), psychiatric (OR 4.14; 95 CI% 1.36-12.61; P?=?.013), dyslipidemia (OR 3.21; 95% CI 1.63-6.35; P?=?.001) and the number of drugs prescribed (OR 4.33; 95% CI 2.40-7.81; P?=?.000). CONCLUSION: The prevalence of potential interactions in COVD 19 patient undergoing treatment with LPV/r is high, with age (>65), ICU admission, previous respiratory and psychiatric pathology, dyslipidemia and the number of prescribed drugs acting as risk factors. äPotential drug-drug interactions in COVID 19 patients in treatment wit(epmc).pdf DeepDyve Pubget Overpricing